LifeMax Healthcare International

LifeMax Healthcare International is a clinical-stage biotechnology company dedicated to developing first-in-class or best-in-class therapeutics for orphan diseases with significant unmet medical needs. Founded in 2014 by industry veteran Dr. Larry Hsu, the company operates through its subsidiaries, LifeMax Laboratories and LifeMax Biotechnology, and its affiliate AmMax Bio. Its lead program, LM-030 (BPR-277), is a topical small molecule inhibitor of KLK7 and ELA2 currently in pivotal Phase 2/3 trials for Netherton Syndrome, a rare and life-threatening genetic skin disorder. The company also advances AMB-051 (AMG 820), a CSF-1R monoclonal antibody licensed from Amgen, for Tenosynovial Giant Cell Tumors and other orphan indications like idiopathic pulmonary fibrosis. LifeMax leverages its deep expertise in drug development and proprietary delivery technology to address the underlying genetic abnormalities of rare conditions.